Ascentage Pharma Group International Future Growth
Future criteria checks 2/6
Ascentage Pharma Group International is forecast to grow earnings and revenue by 17.7% and 33.1% per annum respectively. EPS is expected to grow by 17.8% per annum. Return on equity is forecast to be -119% in 3 years.
Key information
17.7%
Earnings growth rate
17.8%
EPS growth rate
| Biotechs earnings growth | 36.2% |
| Revenue growth rate | 33.1% |
| Future return on equity | -119.0% |
| Analyst coverage | Low |
| Last updated | 02 Apr 2024 |
Recent future growth updates
Recent updates
Here's Why Ascentage Pharma Group International's (HKG:6855) CEO May Not Expect A Pay Rise This Year
May 03
Why We're Not Concerned Yet About Ascentage Pharma Group International's (HKG:6855) 30% Share Price Plunge
Mar 30Are Investors Undervaluing Ascentage Pharma Group International (HKG:6855) By 40%?
Feb 17There's Reason For Concern Over Ascentage Pharma Group International's (HKG:6855) Price
Dec 20Ascentage Pharma Group International (HKG:6855) Is Making Moderate Use Of Debt
Oct 28Some Analysts Just Cut Their Ascentage Pharma Group International (HKG:6855) Estimates
Aug 27There's Reason For Concern Over Ascentage Pharma Group International's (HKG:6855) Price
Aug 23Ascentage Pharma Group International (HKG:6855) Is Carrying A Fair Bit Of Debt
Jun 19Ascentage Pharma Group International (HKG:6855) Has Debt But No Earnings; Should You Worry?
Dec 04Is Ascentage Pharma Group International (HKG:6855) A Risky Investment?
Aug 30Does Ascentage Pharma Group International (HKG:6855) Have A Healthy Balance Sheet?
Oct 04An Intrinsic Calculation For Ascentage Pharma Group International (HKG:6855) Suggests It's 39% Undervalued
Jul 05The Ascentage Pharma Group International (HKG:6855) Share Price Has Gained 37% And Shareholders Are Hoping For More
Mar 01Is Ascentage Pharma Group International (HKG:6855) Popular Amongst Institutions?
Jan 26Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 588 | -577 | N/A | N/A | 1 |
| 12/31/2025 | 528 | -620 | -583 | -573 | 2 |
| 12/31/2024 | 300 | -809 | -672 | -662 | 1 |
| 12/31/2023 | 222 | -926 | -783 | -726 | N/A |
| 9/30/2023 | 239 | -902 | -798 | -707 | N/A |
| 6/30/2023 | 257 | -879 | -814 | -687 | N/A |
| 3/31/2023 | 233 | -881 | -852 | -671 | N/A |
| 12/31/2022 | 210 | -883 | -891 | -654 | N/A |
| 9/30/2022 | 160 | -848 | -922 | -620 | N/A |
| 6/30/2022 | 111 | -812 | -954 | -586 | N/A |
| 3/31/2022 | 69 | -797 | -997 | -595 | N/A |
| 12/31/2021 | 28 | -782 | -1,041 | -605 | N/A |
| 9/30/2021 | 25 | -759 | -1,021 | -635 | N/A |
| 6/30/2021 | 23 | -735 | -1,000 | -665 | N/A |
| 3/31/2021 | 18 | -706 | -931 | -637 | N/A |
| 12/31/2020 | 12 | -678 | -861 | -610 | N/A |
| 9/30/2020 | 14 | -922 | -798 | -576 | N/A |
| 6/30/2020 | 15 | -1,167 | -735 | -542 | N/A |
| 3/31/2020 | 15 | -1,324 | -638 | -501 | N/A |
| 12/31/2019 | 15 | -1,481 | -542 | -460 | N/A |
| 9/30/2019 | 11 | -1,171 | -454 | -399 | N/A |
| 6/30/2019 | 7 | -862 | -366 | -338 | N/A |
| 3/31/2019 | 7 | -604 | -310 | -288 | N/A |
| 12/31/2018 | 7 | -345 | -253 | -238 | N/A |
| 12/31/2017 | 6 | -119 | -129 | -108 | N/A |
| 12/31/2016 | 8 | -108 | N/A | -46 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 6855 is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: 6855 is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: 6855 is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: 6855's revenue (33.1% per year) is forecast to grow faster than the Hong Kong market (8.1% per year).
High Growth Revenue: 6855's revenue (33.1% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 6855 is forecast to be unprofitable in 3 years.